A new study shows that in patients with multiple sclerosis who exhibit active disease despite disease-modifying therapy, a switch to fingolimod is more effective than continuation of IFN-β or glatiramer acetate for preventing relapses and worsening of disability. These data support the utility of treatment escalation to improve disease control.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
He, A. et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol. http://dx.doi.org/10.1001/jamaneurol.2014.4147.
Butzkueven, H. et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult. Scler. 12, 769–774 (2006).
Bergvall, N. et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS ONE 9, e88472 (2014).
Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402–415 (2010).
Cohen, J. A. et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J. Neurol. 260, 2023–2032 (2013).
Khatri, B. et al. Comparison of fingolimod with interferon beta-1a in relapsing–remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 10, 520–529 (2011).
Anglemyer, A., Horvath, H. T. & Bero, L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: MR000034. http://dx.doi.org/10.1002/14651858.MR000034.pub2.
Austin, P. C. & Laupacis, A. A tutorial on methods to estimating clinically and policy-meaningful measures of treatment effects in prospective observational studies: a review. Int. J. Biostat. 7, 6 (2011).
Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278–286 (2014).
Rotstein, D. L., Healy, B. C., Malik, M. T., Chitnis, T. & Weiner, H. L. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 72, 152–158 (2015).
I.T.R. is supported by National Multiple Sclerosis Society Sylvia Lawry Physician Fellowship Award FP 17106-A-1.
J.A.C. reports personal compensation for consulting from Genentech. I.T.R. declares no competing interests.
About this article
Cite this article
Rossman, I., Cohen, J. Switching sides—fingolimod versus injectable MS therapies. Nat Rev Neurol 11, 316–317 (2015). https://doi.org/10.1038/nrneurol.2015.59